News | March 11, 2023
Marksans Pharma announces USFDA approval for Famotidine Tablets
Marksans' OTC Famotidine Tablets USP are acid reducers
Marksans' OTC Famotidine Tablets USP are acid reducers
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The cash consideration for the above acquisition will be Euro 26 million.
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The product will be launched by NATCO's commercial partner Viatris.
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
Subscribe To Our Newsletter & Stay Updated
